Qiagen s Q2 Revenues Jump 24 Percent; Announces Deals With Bayer, Genicon | GenomeWeb

NEW YORK, Aug. 6 – Qiagen on Monday reported a 24 percent surge in second-quarter revenues from the same period one year ago as demand for the company’s nucleic acid reagents and research tools continued to climb.

Revenue for the quarter ended June 30 totaled $66.0 million, up from $53.3 million during the second quarter 2000. Net earning for the recent period came in at $11.3 million, or 8 cents per share, compared with $1.8 million, or 1 cent er share, year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.